Biogen Inc.’s drug for a rare form of amyotrophic lateral sclerosis was approved by U.S. regulators, marking the first clearance of a treatment targeting a specific genetic cause of the incurable paralysis disease. The Food and Drug Administration granted clearance for the drug, called Qalsody, through an accelerated approval pathway, meaning Biogen must conduct more research to establish its benefits for it to remain on the market.